Flu iiq


13 Jun 2018

New translations added

Several new translations of the flu-iiQTM are now available, including Hindi, Bengali, Arabic, Hebrew, Lithuanian, Italian, Slovak and Vietnamese. See the full list of over 50 translations here

05 May 2016

Three more translations now available

The flu-iiQTM is now available in Tamil, Malay and Chinese suitable for use in Malaysia and Singapore. See the full list of translated versions here

01 Dec 2015

Five new flu-iiQTM translations now available

The flu-iiQTM is now available in Turkish, Chinese (traditional script for Hong Kong), Thai, Tagalog & Hiligaynon (Philippines). The flu-iiQTM licence fee includes the use of any of the existing 36 translated versions – so for many studies using the flu-iiQTM there will be no translation fees.

18 Mar 2015

Flu-iiQTM included in FDA sponsored global initiative that enables information system interoperability to improve medical research

The Clinical Data Interchange Standards  (CDISC) is a global, open, multidisciplinary, non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical research data and metadata. The CDISC mission is to develop and support global, platform-independent data standards that enable information system interoperability to improve medical research and related areas of healthcare.  CDISC standards are vendor-neutral, platform-independent and freely available via the CDISC website.

As part of this effort, CDISC has created a standard implementation supplement for the flu-iiQTM.
For further information please visit the CDISC website.

09 Apr 2014

flu-iiQTM used in a global vaccine trial

In a paper recently published regarding a large trial in which the flu-iiQTM was used the authors conclude:

“To our knowledge, this is the first clinical efficacy trial of an influenza vaccine to report PROs due to the previous lack of a valid and reliable measure for influenza. Currently, complete prevention of influenza illness through vaccination appears to be unachievable, and thus, the primary aim of vaccination in elderly people may lie in the prevention of severe illness and reduction in morbidity and burden of influenza-associated complications. Such outcomes are ideally measured by PROs, which are relevant in the real-life setting and capture the experience of patients.”

Gerrit A van Essen, Jiri Beran, Jeanne-Marie Devaster, Christelle Durand, Xavier Duval, Meral Esen, Ann R Falsey, Gregory Feldman, Pierre Gervais, Bruce L. Innis, Martina Kovac, Odile Launay, Geert Leroux-Roels, Janet  E McElhaney, Shelly McNeil, Mohammed Oujaa, Jan Hendrik Richardus, Guillermo Ruiz-Palacios, Richard H Osborne and Lidia Oostvogels. (2014) Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. Influenza and Other Respiratory Viruses 00(00), 000–000. doi:10.1111/irv.12245.


13 Jan 2014

Swedish & Spanish flu-iiQTM now available

The flu-iiQTM questionnaire is now available in Spanish (Spain) and Swedish.

18 Aug 2013

Use of the flu-iiQTM in a recent large clinical study

The contribution of the flu-iiQTM in a large clinical trial will be presented at the Options for Influenza Control VIII conference in a poster presentation:

Influenza symptoms and impact on quality of life in elderly adults: effect of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines.

Poster P2-505

18 Aug 2013

flu-iiQTM at Options for the Control of Influenza VIII Conference, Cape Town 5-9th Sept 2013

Meet with Dr Richard Osborne, author of the flu-iiQTM at our booth in the main exhibition hall at Options VIII a major international influenza control conference.

20 Jul 2013

new Hungarian & Latvian flu-iiQTM translations

Hungarian and Latvian have been added to the 25+ languages in which the flu-iiQTM is currently available.

20 Jul 2013

Options for Control of Influenza conference

Dr Richard Osborne will be attending the Options for Control of Influenza conference in Cape Town, South Africa on 5-10 September. He will be presenting a study in which the flu-iiQTM was used as an outcome measure in a global influenza trial.
More details to follow.